Nidanilimab( —— )

Catalog No. M36753 CAS No. 2171061-85-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Nidanilimab
Note

Research use only, not for human use.
Brief Description

Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells.
Description

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
In Vitro

——
In Vivo

Animal Model:Nude C57Bl/6 mice with LU2503 NSCLC PDX model Dosage:10 mg/kg Administration:Intraperitoneal injection Result:Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
Synonyms

——
Pathway

Apoptosis
Target

IL Receptor
Recptor

IL Receptor
Research Area

——
Indication

——

1. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.

Calculator

molnova catalog